TY - JOUR T1 - Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. AU - Monami,M, AU - Lamanna,C, AU - Marchionni,N, AU - Mannucci,E, Y1 - 2009/03/19/ PY - 2009/3/21/entrez PY - 2009/3/21/pubmed PY - 2009/7/30/medline SP - 220 EP - 2 JF - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association JO - Exp Clin Endocrinol Diabetes VL - 117 IS - 5 N2 - BACKGROUND: Continuous Subcutaneous Insulin Infusion (CSII) improves HbA1c in type 1 diabetic patients unsatisfactorily controlled by Multiple Daily Injections (MDI). Few trials have explored CSII for basal-bolus therapy in type 2 diabetes. MATERIALS AND METHODS: Randomized Clinical Trials (RCTs) comparing CSII and MDI for at least 12 weeks in type 2 diabetic patients were retrieved, assessing between-group differences in HbA1c and insulin daily dose at endpoint, and incidence of hypoglycemia. RESULTS: A total of 4 RCTs was included in the analysis. CSII did not produce any significant improvement of HbA1c in comparison with MDI (Standardized difference in mean: 0.09(-0.08;0.26)%; p=0.31). No significant difference was observed in the rate of hypoglycemic episodes. CSII was associated with a nonsignificant trend toward the reduction of insulin doses used at the end of trial. CONCLUSIONS: Available data do not justify the use of CSII for basal-bolus insulin therapy in type 2 diabetes. SN - 1439-3646 UR - https://www.unboundmedicine.com/medline/citation/19301231/Continuous_subcutaneous_insulin_infusion_versus_multiple_daily_insulin_injections_in_type_2_diabetes:_a_meta_analysis_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0028-1119405 DB - PRIME DP - Unbound Medicine ER -